Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
PTC Therapeutics (PTCT)
NASDAQ:PTCT
Holding PTCT?
Track your performance easily
PTCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$17.53 - $40.69
Previous Close$33.77
Volume563.92K
Average Volume (3M)692.96K
Market Cap
$2.60B
Enterprise Value$1.90B
Total Cash (Recent Filing)$1.09B
Total Debt (Recent Filing)$395.50M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Oct 24, 2024EPS Estimate
-$1.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.32
Shares Outstanding76,924,170
10 Day Avg. Volume537,530
30 Day Avg. Volume692,964
Standard Deviation0.14
R-Squared0.06
Alpha-0.00136
Financial Highlights & Ratios
Price to Book (P/B)-2.65
Price to Sales (P/S)2.90
Price to Cash Flow (P/CF)-9.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.11
Enterprise Value/Gross Profit2.18
Enterprise Value/Ebitda-10.02
Forecast
1Y Price Target
$40.00Price Target Upside14.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
PTC Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company reported 2Q24 total revenue of $186.7M, above analyst estimates of $156.2M and consensus of $178.3M.
Pipeline PotentialSepiapterin for PKU is seen as the most notable opportunity for PTCT, with a large opportunity due to the number of PKU patients not well-controlled on existing treatments.
Regulatory DevelopmentsPTCT is preparing to meet with the FDA to discuss the potential for accelerated approval for PTC518 in Huntington's disease (HD).
Bears Say
Market AuthorizationCHMP issued a negative opinion on the renewal of Translarna's conditional marketing authorization for nonsense mutation Duchenne muscular dystrophy in the EU.
Regulatory IssuesThe FDA requested additional information for the Translarna NDA resubmission, raising concerns about potential delays in approval.
Revenue SustainabilityThe durability of Translarna sales in the EU remains uncertain, leading to downside risks to the stock.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PTCT FAQ
What was PTC Therapeutics’s price range in the past 12 months?
PTC Therapeutics lowest stock price was $17.53 and its highest was $40.69 in the past 12 months.
What is PTC Therapeutics’s market cap?
Currently, no data Available
When is PTC Therapeutics’s upcoming earnings report date?
PTC Therapeutics’s upcoming earnings report date is Oct 24, 2024 which is in 36 days.
How were PTC Therapeutics’s earnings last quarter?
PTC Therapeutics released its earnings results on Aug 08, 2024. The company reported -$1.29 earnings per share for the quarter, missing the consensus estimate of -$1.12 by -$0.17.
Is PTC Therapeutics overvalued?
According to Wall Street analysts PTC Therapeutics’s price is currently Undervalued.
Does PTC Therapeutics pay dividends?
PTC Therapeutics does not currently pay dividends.
What is PTC Therapeutics’s EPS estimate?
PTC Therapeutics’s EPS estimate is -$1.51.
How many shares outstanding does PTC Therapeutics have?
PTC Therapeutics has 76,924,170 shares outstanding.
What happened to PTC Therapeutics’s price movement after its last earnings report?
PTC Therapeutics reported an EPS of -$1.29 in its last earnings report, missing expectations of -$1.12. Following the earnings report the stock price went down -3.575%.
Which hedge fund is a major shareholder of PTC Therapeutics?
Among the largest hedge funds holding PTC Therapeutics’s share is Blackstone Inc.. It holds PTC Therapeutics’s shares valued at 33M.
---
PTC Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$40.00 (14.06% Upside)
$40.00 (14.06% Upside)
Blogger Sentiment
Bullish
PTCT Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 11.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $77.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.59%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
43.21%
Trailing 12-Months
Company Description
PTC Therapeutics
PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
---
PTCT Earnings Call
Q2 2024
0:00 / 0:00
---
PTCT Stock 12 Month Forecast
Average Price Target
$40.00
▲(14.06% Upside)
Technical Analysis
Sarepta Therapeutics
―
BioMarin Pharmaceutical
―
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Best Analysts Covering PTCT
1 Year
1 Year Success Rate
12/14 ratings generated profit
1 Year Average Return
+36.12%
initiated a buy rating 15 days ago
Copying Joel Beatty's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +36.12% per trade.
---